Diaceutics (LON:DXRX) Stock Price Expected to Rise, Shore Capital Analyst Says

Diaceutics (LON:DXRX) had its target price raised by investment analysts at Shore Capital from GBX 180 to GBX 215 in a research note issued to investors on Thursday,London Stock Exchange reports. The firm currently has a “buy” rating on the stock. Shore Capital’s target price indicates a potential upside of 37.82% from the stock’s current price.

Diaceutics Trading Up 10.2%

DXRX traded up GBX 14.50 on Thursday, reaching GBX 156. 248,932 shares of the company’s stock were exchanged, compared to its average volume of 286,775. Diaceutics has a twelve month low of GBX 106 and a twelve month high of GBX 168. The company’s 50 day moving average is GBX 144.13 and its 200-day moving average is GBX 143.73. The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The company has a market cap of £132.02 million, a price-to-earnings ratio of -86.67 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.